Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Almeida L, Rocha JF, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P.

Clin Pharmacokinet. 2013 Feb;52(2):139-51. doi: 10.1007/s40262-012-0024-7.

PMID:
23248072
2.

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Rocha JF, Almeida L, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P.

Br J Clin Pharmacol. 2013 Nov;76(5):763-75. doi: 10.1111/bcp.12081.

3.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P.

Eur J Clin Pharmacol. 2014 Sep;70(9):1059-71. doi: 10.1007/s00228-014-1701-2. Epub 2014 Jun 14.

PMID:
24925090
4.

Effect of moderate liver impairment on the pharmacokinetics of opicapone.

Rocha JF, Santos A, Falcão A, Lopes N, Nunes T, Pinto R, Soares-da-Silva P.

Eur J Clin Pharmacol. 2014 Mar;70(3):279-86. doi: 10.1007/s00228-013-1602-9. Epub 2013 Nov 24.

PMID:
24271646
5.
6.

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.

Clin Ther. 2009 Oct;31(10):2258-71. doi: 10.1016/j.clinthera.2009.10.019.

PMID:
19922897
7.

Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.

Ferreira JJ, Rocha JF, Falcão A, Santos A, Pinto R, Nunes T, Soares-da-Silva P.

Eur J Neurol. 2015 May;22(5):815-25, e56. doi: 10.1111/ene.12666. Epub 2015 Feb 4.

PMID:
25649051
8.

Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.

Bonifácio MJ, Sutcliffe JS, Torrão L, Wright LC, Soares-da-Silva P.

Neuropharmacology. 2014 Feb;77:334-41. doi: 10.1016/j.neuropharm.2013.10.014. Epub 2013 Oct 19.

PMID:
24148813
9.

Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.

Bonifácio MJ, Torrão L, Loureiro AI, Palma PN, Wright LC, Soares-da-Silva P.

Br J Pharmacol. 2015 Apr;172(7):1739-52. doi: 10.1111/bph.13020. Epub 2015 Jan 20.

10.

Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.

Gonçalves D, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Toxicol Appl Pharmacol. 2017 May 15;323:9-15. doi: 10.1016/j.taap.2017.03.013. Epub 2017 Mar 16.

PMID:
28322896
11.

A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.

Gonçalves D, Alves G, Fortuna A, Bonifácio MJ, Soares-da-Silva P, Falcão A.

Neuropharmacology. 2017 Oct;125:146-155. doi: 10.1016/j.neuropharm.2017.07.019. Epub 2017 Jul 19.

PMID:
28734868
12.

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.

Vaz-da-Silva M, Loureiro AI, Nunes T, Lopes C, Rocha J, Machado R, Costa R, Torrão L, Falcão A, Wright L, Almeida L, Soares-da-Silva P.

Drugs R D. 2008;9(6):435-46. doi: 10.2165/0126839-200809060-00006.

PMID:
18989992
14.

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators.

Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.

PMID:
26725544
15.

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.

Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.

Clin Pharmacol Ther. 1997 Sep;62(3):300-10.

PMID:
9333106
16.

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.

Silveira P, Vaz-da-Silva M, Almeida L, Maia J, Falcão A, Loureiro A, Torrão L, Machado R, Wright L, Soares-da-Silva P.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):603-9. Epub 2003 Sep 27.

PMID:
14517707
17.

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.

Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P.

Clin Pharmacol Ther. 1995 May;57(5):508-17.

PMID:
7768073
18.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators.

JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.

PMID:
28027332
19.

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.

Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18. doi: 10.1097/wnf.0b013e3180645cb0.

PMID:
18303486
20.

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.

Almeida L, Vaz-da-Silva M, Silveira P, Falcão A, Maia J, Loureiro A, Torrão L, Machado R, Wright L, Soares-da-Silva P.

Clin Neuropharmacol. 2004 Jan-Feb;27(1):17-24.

PMID:
15090932

Supplemental Content

Support Center